[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fq9LsQaeIiTlw_Q8CdgwO6QAWbZLfoMOSAdaBxJ1yb4A":8,"$fe0p3M_IzeHbllDUYR24cMbLjWlYMX1NJjL2Ko73DJ_Y":55,"$f1FSjPkeuS6B9UJOI_H7Ff9C-gJkP4p4fnaRvluiVT7Q":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68490,870802,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//mjO9jf1s5tivggM4Uk0XJhNfN0KmGeSV.png","何丽萍","浙江大学医学院附属第一医院","肿瘤科","住院医师",10,0,"💊 直肠癌肝转移：KRAS G12D突变患者的FOLFIRI+贝伐治疗指南","","https://ystcdn.venuertc.com/venue/AI/a804cc85-b970-42fc-b834-8917aa9f724b.jpg","\u003Cdiv class=\"colorectal-material-container\">\n  \u003Ch1 id=\"material_title\" class=\"colorectal-material-title\">\n    💊 直肠癌肝转移：KRAS G12D突变患者的FOLFIRI+贝伐治疗指南\n  \u003C/h1>\n\n  \u003C!-- 开头引入 -->\n  \u003Csection class=\"colorectal-material-section colorectal-material-intro\">\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(90deg, #f3f6f9 60%, #e7f0ed 100%); padding:22px 15px; border-radius:16px;\">\n      说起来，FOLFIRI和贝伐珠单抗已经成为很多肿瘤化疗方案中的常见组合。它们分别代表化疗和靶向药物，针对特定基因突变（比如KRAS G12D）有着特殊意义。本篇文章将用7个详细要点，帮你把握这种联合用药的基本规则和细致技巧，包括剂型、服用方法、相互作用、不良反应以及储存细则，为安全高效用药保驾护航。\u003Cspan style=\"font-size:1.1em;\">✨\u003C/span>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 01 药品成分和剂型 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">01 FOLFIRI和贝伐的成分及剂型选择 🧬\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(100deg, #f5efe7 60%, #e9e9fa 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>\u003Cstrong>FOLFIRI方案\u003C/strong>包含三种药物：伊立替康、亚叶酸钙、氟尿嘧啶。这些都是注射剂型，需通过静脉给药，药品规格依实际开具为主。\u003C/li>\n        \u003Cli>\u003Cstrong>贝伐珠单抗\u003C/strong>是一种人源化单抗注射液，通常标准规格为100mg/4ml或400mg/16ml，采用静脉输注方式。\u003C/li>\n      \u003C/ul>\n      正确做法：务必确认药品标签和药瓶规格，配药时遵循药房和护士的专业流程，不要随意拆卸或混用不同批次药品。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 药理作用机制分解 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">02 药品作用机制简述 🚀\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(90deg, #eaf6fe 80%, #f5f6f5 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>\u003Cstrong>伊立替康\u003C/strong>：通过抑制DNA复制酶，使肿瘤细胞无法快速分裂，属于细胞毒性药物（参考：Rothenberg et al., J Clin Oncol, 2001）。\u003C/li>\n        \u003Cli>\u003Cstrong>亚叶酸钙\u003C/strong>：增强氟尿嘧啶对靶细胞作用，帮助药效发挥到最大。\u003C/li>\n        \u003Cli>\u003Cstrong>氟尿嘧啶\u003C/strong>：阻断细胞RNA与DNA的合成，干扰肿瘤细胞生长。\u003C/li>\n        \u003Cli>\u003Cstrong>贝伐珠单抗\u003C/strong>：靶向血管内皮生长因子（VEGF），阻止肿瘤新生血管形成，抑制营养供给（Ferrara et al., Nat Rev Drug Discov, 2004）。\u003C/li>\n      \u003C/ul>\n      药品组合的机制决定了抗肿瘤效果，需严格把控给药顺序和配伍方式，不要自行调整。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 用药时间与给药细节 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">03 正确服用时间和给药技巧 ⏰\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(90deg, #f4f8ee 70%, #e2eef7 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>FOLFIRI和贝伐全部为静脉输注药物，必须在医院或专业医疗场所执行，每次给药需遵循固定周期（如2周1次）。\u003C/li>\n        \u003Cli>静脉给药前后建议饮用适量温水，以减少不适；输注过程中应避免剧烈运动。\u003C/li>\n        \u003Cli>贝伐珠单抗的输注时间需根据剂量调整，首次输注时间较长，复用时略短。\u003C/li>\n      \u003C/ul>\n      正确做法：听从护士安排，保证静脉注射过程中有足够休息，不要自行提前结束输液或调整速度。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 用药剂量与周期管理 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">04 剂量管理与特殊人群的用药调整 📏\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(90deg, #fdeff8 60%, #e7f6ef 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>标准剂量由体表面积和临床经验决定，通常伊立替康每次180mg/m²，氟尿嘧啶和亚叶酸钙参照方案定量，贝伐珠单抗按体重每次5mg/kg静脉输注。\u003C/li>\n        \u003Cli>老年患者（如本案例71岁男性）建议周期内定期评估肝肾功能，必要时适当减量。\u003C/li>\n        \u003Cli>药品调整须由专业医生负责，患者切勿自行增减剂量。\u003C/li>\n      \u003C/ul>\n      案例提醒：有位71岁男性患者使用标准FOLFIRI+贝伐方案后，经过周期评估部分药物进行了剂量微调，减少了副反应发生。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 药物相互作用及搭配规则 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">05 药物相互作用及搭配的关键注意 🚦\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(90deg, #eff5fb 70%, #f6f0ea 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>\u003Cstrong>不得与华法林等抗凝药物同时使用\u003C/strong>，因贝伐珠单抗可能加大出血风险。\u003C/li>\n        \u003Cli>避免与高剂量阿司匹林、非甾体抗炎药（NSAIDs）同服，以防胃肠道损伤加重。\u003C/li>\n        \u003Cli>使用FOLFIRI期间不建议饮酒，酒精可能增强肝毒性。\u003C/li>\n        \u003Cli>不能擅自联合其他化疗药或口服补充剂，具体组合需医生确认。\u003C/li>\n      \u003C/ul>\n      正确做法：提前告知医生所有正在使用的药品及健康补充剂，避免潜在不良交互。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 最常见不良反应与处理 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">06 常见不良反应和应对方法 ⛑️\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(90deg, #f6f7fa 70%, #e7f8ee 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>FOLFIRI方案常见副作用包括脱发、白细胞减少、消化道反应。临床数据显示，白细胞减少发生率达60%（Douillard et al., J Clin Oncol, 2000）。\u003C/li>\n        \u003Cli>贝伐珠单抗可能导致高血压、蛋白尿及轻度疲乏，严重者偶有出血风险。\u003C/li>\n        \u003Cli>如注射后出现皮疹、明显头晕或呼吸困难，需立即向医疗人员报告。\u003C/li>\n      \u003C/ul>\n      正确做法：出现副作用后首先通知医生，部分可通过减量或对症治疗缓解，勿自行停药。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 储存条件与过期处理规范 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">07 药品储存要求与过期处理 🧊\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(96deg, #f6f4f7 60%, #e8f3fa 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>所有注射类药物应在2～8℃下冷藏保存，避免冷冻，开封后建议当天使用。\u003C/li>\n        \u003Cli>药品避光存放，勿置于阳光直射处。\u003C/li>\n        \u003Cli>过期药品不可继续使用，应按医院或药房的规范处置，不要随意丢弃。\u003C/li>\n      \u003C/ul>\n      正确做法：检查包装上的有效期和完整性，每次调配药品前仔细核对标签信息。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 漏服、过量处理和安全建议 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">08 漏服与过量处理原则  🚨\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(90deg, #fef6ea 60%, #eaf6f7 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>如因特殊情况漏服某一周期，应及时联系医院，由医生判定是否补充和调整下次用药方案。\u003C/li>\n        \u003Cli>过量用药可能引发严重毒性反应，包括骨髓抑制及器官损伤，发现输注错误要及时就医。\u003C/li>\n        \u003Cli>所有输注强药都必须按照医嘱执行，用药出现任何意外不可自行处置。\u003C/li>\n      \u003C/ul>\n      正确做法：每次输注前主动核对用药方案和剂量，疑问请与医护人员沟通确认，切勿自行处理偏差。\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 用药实际案例区域 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">09 临床用药案例参考 🩺\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(88deg, #f6f4fa 60%, #ecfaee 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cul class=\"colorectal-material-list\">\n        \u003Cli>一位71岁男性患者接受标准FOLFIRI+贝伐方案，治疗过程中因中性粒细胞减少，及时调整伊立替康和氟尿嘧啶剂量，副作用明显下降。\u003C/li>\n        \u003Cli>临床中，部分老年患者在用药期间加强血压监测，提早识别并处理贝伐相关高血压问题，保障安全。\u003C/li>\n        \u003Cli>按说明书标准储存药品，有效减少药物失效风险，提高整体治疗效果。\u003C/li>\n      \u003C/ul>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 10 总结、实用提醒与安全建议结束语 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">10 总结与用药安全关键点 🔐\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(92deg, #f7faef 60%, #e5f7fa 100%); padding:22px 15px; border-radius:16px;\">\n      \u003Cp>\n        总结来看，FOLFIRI+贝伐联合用药在KRAS G12D突变患者中具有特定优势，但只有严格遵循剂型选择、给药方法、周期和剂量，以及注意药物相互作用和副作用，才能实现最佳效果。特别需要重视药品的专业保存、过期处理、以及输注细则。遇到用药异常应第一时间联系医生，不可随意停药和自我处理。\u003Cbr>\n        正确做法就是记牢：\u003Cspan style=\"font-weight:bold;\">专业医嘱、配药流程、用药记录\u003C/span>三步，保障每次治疗都稳妥高效。\n      \u003C/p>\n      \u003Cp>\n        关键提醒：\u003Cbr>\n        \u003Cspan style=\"color:#AA4646;\">1. 不要自行调整或替换药品组合。\u003C/span>\u003Cbr>\n        \u003Cspan style=\"color:#333;\">2. 一旦出现副作用，切勿自行停药。\u003C/span>\n      \u003C/p>\n      \u003Cp>\n        有效用药的基础，是规范执行每一个细节。实际操作中请始终以医生和药师建议为先。如遇不确定情况，及时沟通和就医才是最安全的选择。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 参考文献区域 -->\n  \u003Csection class=\"colorectal-material-section\">\n    \u003Ch2 class=\"colorectal-material-subtitle\">参考资料 📚\u003C/h2>\n    \u003Cdiv class=\"colorectal-material-bg\"\n         style=\"background: linear-gradient(90deg, #f9f9f9 60%, #eaf6fa 100%); padding:15px 12px; border-radius:12px;\">\n      \u003Col class=\"colorectal-material-ref\">\n        \u003Cli>Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., ... & Gruia, G. (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. \u003Ci> The Lancet, 355\u003C/i>(9209), 1041-1047.\u003C/li>\n        \u003Cli>Rothenberg, M. L., Oza, A. M., Biggs, H., et al. (2001). Superiority of irinotecan compared with fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. \u003Ci>J Clin Oncol, 19\u003C/i>(23), 4297-4309.\u003C/li>\n        \u003Cli>Ferrara, N., Hillan, K. J., Gerber, H. P., & Novotny, W. (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. \u003Ci> Nature Reviews Drug Discovery, 3\u003C/i>(5), 391-400.\u003C/li>\n      \u003C/ol>\n      \u003Cdiv style=\"font-size:0.95em; color:#555; margin-top:6px;\">\n        文献引用格式：APA样式\u003Cbr>\n        可在 PubMed 或 Google Scholar 检索原文\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.colorectal-material-container {\n  font-family: \"Segoe UI\", \"Helvetica Neue\", Arial, \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei\", sans-serif;\n  background-color: #f3f6fa;\n  padding: 32px 12%;\n  max-width:1200px;\n  margin:auto;\n  color: #222;\n  letter-spacing: 0.02em;\n}\n.colorectal-material-title {\n  font-size: 2.6em;\n  color: #244b61;\n  font-weight: bold;\n  margin-bottom: 30px;\n  text-align: center;\n  letter-spacing: 0.04em;\n}\n.colorectal-material-section {\n  margin-bottom: 40px;\n}\n.colorectal-material-subtitle {\n  font-size: 1.5em;\n  color: #33789c;\n  font-weight: 600;\n  margin:40px 0 18px 0;\n  line-height: 1.3;\n  text-shadow: 0 2px 8px #e1eaf1;\n}\n.colorectal-material-bg {\n  min-height: 60px;\n  box-shadow: 0 2px 10px #e3ebf5;\n}\n.colorectal-material-list {\n  margin: 0 0 14px 22px;\n  padding: 0;\n  font-size: 1.08em;\n}\n.colorectal-material-list li {\n  margin-bottom: 8px;\n  padding-left: 4px;\n  line-height: 1.75;\n}\n.colorectal-material-ref {\n  margin: 0 0 0 22px;\n  font-size: 1em;\n}\n.colorectal-material-container p {\n  font-size: 1.12em;\n  line-height: 1.78;\n  margin-bottom: 7px;\n}\n@media screen and (max-width: 900px) {\n  .colorectal-material-container { padding:28px 2%;}\n  .colorectal-material-title { font-size:2em;}\n  .colorectal-material-subtitle{font-size:1.2em;}\n}\n\u003C/style>","\u003Cdiv class=\"colorectal-material-container\">\n  \u003Ch1 id=\"material_title\" class=\"colorectal-material-tit",507,"2025-10-25 00:01:42","直肠癌, KRAS G12D, FOLFIRI, 贝伐珠单抗, 化疗方案, 用药安全, 药物相互作用, 服用指南, 不良反应, 老年患者, 剂量管理, 治疗效果","本指南提供FOLFIRI+贝伐治疗KRAS G12D突变直肠癌的实用信息，涵盖剂型、给药方法、副作用及安全措施，助力患者实现最佳疗效。","2025-11-11 09:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":20,"result":57,"totalSize":21},[],{"code":9,"msg":10,"message":6,"data":59,"success":54},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]